NASDAQ: SABS
Sab Biotherapeutics Inc Stock Ownership - Who owns Sab Biotherapeutics?

Insider buying vs selling

Have Sab Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew MoinDirector2025-09-291,740,000$1.75
$3.05MBuy
Sessa Capital Master LPDirector2025-09-291,740,000$1.75
$3.05MBuy

1 of 1

SABS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SABS insiders and whales buy or sell their stock.

SABS Shareholders

What type of owners hold Sab Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Christine E. Hamilton12.35%11,237,694$39.33MInsider
Edward D. Hamilton11.02%10,023,848$35.08MInsider
Andrew Moin7.45%6,783,028$23.74MInsider
Ilan Katz6.70%6,097,150$21.34MInsider
Eddie Joe Sullivan5.75%5,232,304$18.31MInsider
Samuel J. Reich4.19%3,814,524$13.35MInsider
Big Cypress Holdings LLC3.35%3,047,825$10.67MInsider
Helen K. Ellias3.14%2,857,142$10.00MInsider
Sessa Capital Master LP2.42%2,198,457$7.69MInsider
Jeffrey G. Spragens0.43%394,989$1.38MInsider

1 of 3

SABS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SABS0.08%56.99%Net Buying
ABEO0.07%75.06%Net SellingNet Selling
IKT0.08%20.55%Net BuyingNet Buying
QTTB0.07%76.92%Net BuyingNet Buying
VNDA0.08%69.36%Net Selling

Sab Biotherapeutics Stock Ownership FAQ

Who owns Sab Biotherapeutics?

Sab Biotherapeutics (NASDAQ: SABS) is owned by 0.08% institutional shareholders, 56.99% Sab Biotherapeutics insiders, and 42.94% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 12.35% of the company. Christine E. Hamilton's Sab Biotherapeutics shares are currently valued at $39.44M.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.